A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1428 participants.

Also called NCT04537923

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,428 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04537923
  • EudraCT 2020-000284-23
Other papers using this trial's data
  • Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial JAMA, 2023-11-07 DOI, PubMed 37786396, PMC10548360 PubMed links an erratum for this paper. Erratum: PMID 37883095; Erratum: PMID 40136274 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Belgium, Brazil, Czechia, Germany, Greece, Hungary, Italy, Mexico, Puerto Rico, Romania, Russia, Slovakia, Spain, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04537923. Randomized; no masking; primary purpose treatment. Start 2020-10-19 (actual); primary completion 2022-10-11 (actual). Results posted on 2023-11-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Acronym
SURPASS-6
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Insulin Lispro (U100)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04537923
Content hash
6f131ee5e5bcf03b8191df078bc76238e1de687a4c11697f561ffd3b7da07898